Scientists are not yet sure if the deficiency is the cause of mental health issues or merely the result
GLP-1 (Glucagon-like Peptide-1) is a natural incretin hormone that: Stimulates insulin secretion (when glucose is high) Suppresses glucagon release Slows gastric emptying Increases satiety reducing food intake Why GLP-1 Therapy Stands Out Glycemic Control Lowers HbA1c by ~11.5% with minimal hypoglycemia risk Weight Loss 515 kg depending on drug/dose (semaglutide leads the way) Cardiovascular Protection Reduced major CV events (MACE) in trials like LEADER, SUSTAIN, REWIND Renal Protection Slows progression of diabetic kidney disease Convenience Available as daily or weekly injections and even oral semaglutide Key Clinical Trials LEADER (Liraglutide) CV mortality & MACE SUSTAIN-6 (Semaglutide) CV events & strong weight loss REWIND (Dulaglutide) CV protection even in lower-risk populations STEP Trials (Semaglutide) Double-digit weight reduction in obesity The Bigger Picture GLP-1 therapy goes beyond insulin and beyond diabetes
1 Brands recognize that launching an AG at the moment of generic entry increases their own profits while simultaneously slashing the profits of their rivals
While semaglutide does not directly increase estrogen, the weight loss it produces can reduce excess aromatase activity and normalize estrogen ratios, particularly in women who are carrying excess visceral fat
FDA Patient Information Sheet
9 Redox nanotechnology and glutathione-responsive therapies Redox nanotechnology leverages the abnormal oxidativereductive balance found in tumors to enable precise, stimulus-responsive treatments
